Clinical trials: Lipoprotein(a)
Cardiovascular Disease
Clinico-biological Collection of Subjects With Hyper Lipoprotein a in Reunion Island
Cardiovascular disease (CVD) is the second leading cause of death in France and the leading cause of death on Reunion Island. Some modifiable risk factors for cardiovascular diseases are well identified and can be easily…
- Trial name
- COLLIPAR (NCT04310917)
- Testing
- blood lipoprotein (a) test
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
MENINGOCOCCAL INFECTION
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children.
- Trial name
- NCT02531698
- Testing
- Bivalent rLP2086 Vaccine, Licensed pediatric hepatits A vaccine, Normal Saline
- Where
- 15 sites in Finland, Poland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Stroke
Trial to Evaluate the Ability of a Single Infusion of High-Density Lipoprotein (HDL) to Modulate Markers of Cerebral Ischaemia
The plasma concentration of high-density lipoprotein (HDL) can have anti-inflammatory, anti-oxidative and anti-thrombotic effects in addition to being able to remove cholesterol from peripheral tissues for secretion via the…
- Trial name
- REVEAL (NCT00822302)
- Testing
- Reconstituted High Density Lipoprotein, Saline
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- St George's, University of London
Familial Hypercholesterolemia
Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
The primary objective of this study is to measure how LDL apheresis affects levels of inflammatory and cholesterol markers in human beings.
- Trial name
- INFLAME (NCT01138371)
- Testing
- LDL Apheresis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
ACS (Acute Coronary Syndrome), Hyperlipidemia
Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study
The purpose of this study is to determine whether a proactive, EHR-guided approach helps more individuals reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual…
- Conditions
- ACS (Acute Coronary Syndrome), Hyperlipidemia, Dyslipidemia, Low-Density-Lipoprotein-cholesterol Level
- Trial name
- EHR-LOCALE (NCT07685639)
- Testing
- Pharmacist-led lipid optimization pathway
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- University of Alberta
Meningitis, Meningococcal
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
A multicenter phase 3 safety trial in which 5,700 subjects will be assigned in a 2:1 ratio to receive 120 μg rLP2086 vaccine in a 0, 2, 6 month schedule or control.
- Trial name
- NCT01352793
- Testing
- rLP2086 vaccine, control
- Where
- 86 sites in United States, Australia and 10 more
- Volunteers
- 5,715 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that…
- Trial name
- ACT II (NCT01381679)
- Testing
- Ezetimibe
- Volunteers
- 1,682 people
- Sponsor
- Organon and Co
Lipoprotein(a), Lipoprotein(a), Hyper-Lp(a)-Emia
Implementation Research on the LILAC Method to Educate Management of Elevated Lipoprotein(a).
The goal of this observational study is to assess the if short educational videos about #LILAC-for-Lpa are feasible and accepted in improving the confidence, testing, and management on Lipoprotein(a).
- Trial name
- LILAC-UNI (NCT07177612)
- Where
- 3 sites in Australia, Malaysia and 1 more
- Volunteers
- 20,000 people
- Sponsor
- Changi General Hospital
Insight Into the Prevalence of Elevated Lp(a) Among Greek Medical Students
Medical Students' Evaluation of Dyslipidemia and LIPoprotein(a) Study
This cross-sectional study aims to determine the prevalence of elevated Lp(a) levels among volunteer medical students at the Faculty of Medicine, University Hospital of Ioannina, Greece.
- Trial name
- MEDLIP (NCT06482476)
- Testing
- Measurement of Lp(a) levels
- Where
- Greece
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- University of Ioannina
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Elevated Lipoprotein(a), Cardiovascular Diseases
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
This is a single center, open label, single sequence, two-treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of ISIS 681257 on the pharmacokinetics of a single dose of warfarin.
- Trial name
- NCT03426033
- Testing
- ISIS 681257, Warfarin
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akcea Therapeutics
HIV Infections
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.
- Trial name
- NCT00028301
- Testing
- Atazanavir, Lopinavir/Ritonavir
- Where
- 97 sites in United States, Argentina and 13 more
- Sponsor
- Bristol-Myers Squibb
Familial Hypercholesterolemia
A Registration Study for Familial Hypercholesterolemia in Taiwan
Familial hypercholesterolemia (FH) is an inherited disorder of lipoprotein metabolism, transmitted in an autosomal dominant manner and clinically characterized by elevated levels of total cholesterol (TC) and low-density…
- Trial name
- NCT03152656
- Where
- Taiwan
- Volunteers
- 1,000 people
- Sponsor
- National Taiwan University Hospital
Hypercholesterolemia
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
- Trial name
- CLEAR Path 1 (NCT05694260)
- Testing
- Bempedoic acid
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 31 people
- Sponsor
- Esperion Therapeutics, Inc.
Aortic Valve Stenosis, Lipoprotein(a)
Lipoprotein(a) and Progression of Aortic Stenosis
This study is a prospective, observational, two arm parallel group, clinical study involving patients with measurements of Lp(a) and mild to moderate aortic stenosis.
- Trial name
- NCT06648915
- Testing
- Lipoprotein(a)
- Where
- South Korea
- Volunteers
- 364 people
- Sponsor
- Asan Medical Center
Familial Hypercholesterolemia - Homozygous
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to <12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein…
- Trial name
- ORION-19 (NCT06597006)
- Testing
- Inclisiran
- Where
- 19 sites in United States, Austria and 9 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Subarachnoid Hemorrhage
Antiepileptic Drugs and Vascular Risk Markers
The purpose of this study is to determine if certain seizure medications raise levels of cholesterol and other blood components which could increase the risk of heart attacks and strokes.
- Trial name
- NCT00774306
- Testing
- phenytoin, valproate, levetiracetam
- Volunteers
- 52 people
- Sponsor
- Thomas Jefferson University
Healthy, Heart Disease
Family Research Study: Metabolism of Fats and Proteins in Specific Ethnic Groups
The purpose of this study is to determine whether lipoprotein(a), also called Lp(a), is a risk factor for cardiovascular (heart) disease. Lipoproteins are tiny particles that circulate in the blood.
- Trial name
- NCT00853775
- Testing
- No intervention, observational study
- Where
- United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Familial Hypercholesterolemia - Heterozygous
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 6 to <12 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein…
- Trial name
- ORION-20 (NCT06597019)
- Testing
- Inclisiran
- Where
- 66 sites in United States, Argentina and 21 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Meningococcal B Disease
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
The purpose of this study is to investigate the immunogenicity, safety and tolerability of a new vaccine that might prevent meningococcal B disease. The study will be conducted in healthy toddlers aged between 12 and 24 months.
- Trial name
- NCT02534935
- Testing
- rLP2086 vaccine, Pediatric HAV vaccine
- Where
- 25 sites in Australia, Czechia and 2 more
- Volunteers
- 396 people, healthy volunteers welcome
- Sponsor
- Pfizer